收费全文 | 848篇 |
免费 | 161篇 |
国内免费 | 17篇 |
耳鼻咽喉 | 12篇 |
儿科学 | 46篇 |
妇产科学 | 10篇 |
基础医学 | 32篇 |
口腔科学 | 10篇 |
临床医学 | 151篇 |
内科学 | 226篇 |
皮肤病学 | 29篇 |
神经病学 | 43篇 |
特种医学 | 76篇 |
外科学 | 172篇 |
综合类 | 48篇 |
现状与发展 | 20篇 |
预防医学 | 56篇 |
眼科学 | 25篇 |
药学 | 18篇 |
中国医学 | 2篇 |
肿瘤学 | 50篇 |
2024年 | 7篇 |
2023年 | 42篇 |
2021年 | 18篇 |
2020年 | 23篇 |
2019年 | 9篇 |
2018年 | 49篇 |
2017年 | 44篇 |
2016年 | 31篇 |
2015年 | 40篇 |
2014年 | 39篇 |
2013年 | 55篇 |
2012年 | 20篇 |
2011年 | 27篇 |
2010年 | 46篇 |
2009年 | 63篇 |
2008年 | 29篇 |
2007年 | 20篇 |
2006年 | 24篇 |
2005年 | 12篇 |
2004年 | 10篇 |
2003年 | 12篇 |
2002年 | 12篇 |
2001年 | 17篇 |
2000年 | 10篇 |
1999年 | 18篇 |
1998年 | 28篇 |
1997年 | 32篇 |
1996年 | 43篇 |
1995年 | 29篇 |
1994年 | 17篇 |
1993年 | 21篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 10篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 12篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1978年 | 12篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1964年 | 5篇 |
1963年 | 4篇 |
Objectives
Facial lipoatrophy can be a stigmatizing side effect of antiretroviral (AVR) treatment for HIV‐infected patients. We sought to evaluate the long‐term efficacy and safety of a new formulation of hyaluronic acid that can be injected in larger amounts and into deeper skin layers during 3 years of follow‐up.Methods
Twenty patients received injections of Restylane SubQ™. Refill treatment was offered at 12 and 24 months. Treatment effects were evaluated using ultrasound, the Global Aesthetic Improvement Scale, visual analogue scale (VAS) and the Rosenberg self‐esteem scale.Results
Seventeen patients remained at 36 months. Mean (± standard deviation) total cutaneous thickness increased from 6 ± 1 mm at baseline to 12 ± 1 mm (P<0.001) at 36 months. Response rate (total cutaneous thickness >10 mm) was 70%. Fifteen patients classified their facial appearance as very much or moderately improved. VAS increased from 39 ± 25 to 70 ± 20 (P<0.05) and higher self‐esteem scores were reported. Local swelling and tenderness after treatment was common. Persistent papules found in several patients after treatment were removed effectively with hyaluronidase injections. Three patients, treated only at baseline, still had higher total cutaneous thickness scores at 36 months.Conclusions
Our results indicate that a large particle hyaluronic acid formulation is a durable and well‐tolerated dermal filler for treating HIV‐positive patients with facial lipoatrophy.Methods: Systematically searched, randomized, controlled trials (obtained through MEDLINE, EMBASE, Biological Abstracts, manufacturer's database, manual searching of journals, and article reference lists) were analyzed. Relevant end points were prevention of early PONV (within 6 h after surgery) and late PONV (within 48 h) and adverse effects. Relative benefit and number-needed-to-treat were calculated. The number-needed-to-treat indicated how many patients had to be exposed to ondansetron to prevent PONV in one of them who would have vomited or been nauseated had he or she received placebo.
Results: Fifty-three trials were found that had data from 7,177 patients receiving 24 different ondansetron regimens and from 5,712 controls receiving placebo or no treatment. Average early and late PONV incidences without ondansetron were 40% and 60%, respectively. There was a dose response for oral and intravenous ondansetron. Best number-needed-to-treat to prevent PONV with the best documented regimens was between 5 and 6. This was achieved with an intravenous dose of 8 mg and an oral dose of 16 mg. Antivomiting efficacy was consistently better than antinausea efficacy. Efficacy in children was poorly documented. Ondansetron significantly increased the risk for elevated liver enzymes (number-needed-to-harm was 31) and headache (number-needed-to-harm was 36). 相似文献